Evogene Ltd. (EVGN)

Market Cap	11.79M
Revenue (ttm)	9.45M
Net Income (ttm)	-19.87M
Shares Out	5.10M
EPS (ttm)	-3.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	206,933
Open	2.240
Previous Close	2.240
Day's Range	2.020 - 2.240
52-Week Range	2.020 - 10.400
Beta	1.02
Analysts	Strong Buy
Price Target	12.00 (+474.16%)
Earnings Date	Nov 13, 2024

About EVGN

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. The Huma...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 142
• Stock Exchange: NASDAQ
• Ticker Symbol: EVGN
• Website: https://www.evogene.com

Financial Performance

In 2023, Evogene's revenue was $5.64 million, an increase of 236.72% compared to the previous year's $1.68 million. Losses were -$23.88 million, -10.36% less than in 2022.

Analyst Forecast

According to one analyst, the rating for EVGN stock is "Strong Buy" and the 12-month stock price forecast is $12.0.

Price Target

$12.0

(474.16% upside)

Analyst Consensus: Strong Buy